Chronic treatment with epidermal growth factor stimulates growth of the urinary tract in the rat.
Twenty-four male Wistar rats, 8 weeks old, were allocated into three groups and treated with human recombinant epidermal growth factor (EGF) administered subcutaneously in doses of 0, 30, and 150 micrograms/kg per day for 4 weeks. Blood sampling was done every 2nd week and urine sampling was done for 2 consecutive days every week. The most striking finding was that the ureters were dose dependently enlarged, due to growth of all layers of the ureteric wall. The urothelium of the bladder showed considerable hyperplasticity with a widening of the basal proliferative compartment and a normal differentiation pattern as observed by the expression of carbohydrate epitopes, characterized with lectinohistochemistry. Blood examination revealed a decrease in blood haemoglobin concentration and a slight increase in serum creatinine concentration in the high-dose group. There were no effects of EGF on the urinary excretion of electrolytes, proteins, and endogenous EGF.
Vinter-Jensen
L
L
Department of Clinical Biochemistry, Aarhus University Hospital, Denmark.
Smerup
M
M
Jørgensen
P E
PE
Juhl
C O
CO
Orntoft
T
T
Poulsen
S S
SS
Nexø
E
E
D000818:Animals; D003404:Creatinine / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004815:Epidermal Growth Factor / Q000494:pharmacology*; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D037102:Lectins / Q000378:metabolism; D008297:Male; D009994:Osmolar Concentration; D051381:Rats; D017208:Rats, Wistar; D011994:Recombinant Proteins; D013997:Time Factors; D014551:Urinary Tract / Q000033:anatomy & histology / Q000187:drug effects* / Q000254:growth & development*
D006454:Hemoglobins; D037102:Lectins; D011994:Recombinant Proteins; D004815:Epidermal Growth Factor; D003404:Creatinine